Yumeng Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8110865/publications.pdf

Version: 2024-02-01

1683354 1281420 21 131 5 11 citations h-index g-index papers 21 21 21 215 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Oenothein B inhibits human non-small cell lung cancer A549 cell proliferation by ROS-mediated PI3K/Akt/NF-κB signaling pathway. Chemico-Biological Interactions, 2019, 298, 112-120.	1.7	33
2	Large granular lymphocytic leukemia – A retrospective study of 319 cases. American Journal of Hematology, 2021, 96, 772-780.	2.0	26
3	Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein. NeuroMolecular Medicine, 2017, 19, 322-344.	1.8	15
4	Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine. Frontiers in Oncology, 2020, 10, 898.	1.3	15
5	Calorie restriction does not restore brain mitochondrial function in P301L tau mice, but it does decrease mitochondrial F0F1-ATPase activity. Molecular and Cellular Neurosciences, 2015, 67, 46-54.	1.0	12
6	Chronic pain in patients with hemophilia: is it preventable?. Blood Coagulation and Fibrinolysis, 2020, 31, 346-352.	0.5	6
7	The effects of AICAR and rapamycin on mitochondrial function in immortalized mitochondrial DNA mutator murine embryonic fibroblasts. Biology Open, 2018, 7, .	0.6	5
8	T315I-mutated myeloid sarcoma. Leukemia Research Reports, 2019, 12, 100184.	0.2	3
9	Myasthenia Gravis and Large Granular Lymphocytic Leukemia: a rare association. Leukemia Research Reports, 2020, 14, 100226.	0.2	3
10	Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia. Blood, 2019, 134, 1368-1368.	0.6	3
11	Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies. Expert Review of Hematology, 2021, 14, 731-740.	1.0	2
12	Impact of doxycycline on outcomes in AL amyloidosis Journal of Clinical Oncology, 2020, 38, e20568-e20568.	0.8	2
13	Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. American Journal of Hematology, 2022, 97, .	2.0	2
14	Understanding Circulating Large Granular Lymphocytic Proliferations in Cutaneous T-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S273.	0.2	1
15	Clinical characteristics and prognostic factors of 70 patients with $S\tilde{A}$ ©zary syndrome: a single-institutional experience at Moffitt cancer center. Leukemia and Lymphoma, 2021, , 1-8.	0.6	1
16	Will adding alkylating agent to bortezomib improve survival of newly diagnosed AL amyloidosis patients?. Journal of Clinical Oncology, 2020, 38, 8517-8517.	0.8	1
17	Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e770-e776.	0.2	1
18	Clinical Characteristics, Prognosis and Outcome of Patients with Sezary Syndrome at Moffitt Cancer Center: A Single-Institution Cohort. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S358-S359.	0.2	0

YUMENG ZHANG

#	Article	IF	CITATIONS
19	Post-partum cutaneous manifestation of antiphospholipid syndrome. Human Pathology: Case Reports, 2019, 18, 200334.	0.2	0
20	Upfront Targeted Tyrosine Kinase Inhibitor Therapy Improves Outcome in Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia. Blood, 2021, 138, 3658-3658.	0.6	O
21	Clinical Characteristics and Outcomes of Patients with Large Granular Lymphocytic Leukemia Treated with Methotrexate, Cyclophosphamide or Cyclosporine. a Large Single Institutional Retrospective Analysis. Blood, 2020, 136, 36-38.	0.6	0